Tomasz S. Mandat

Prof. Dr. Tomasz S. Mandat

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2016 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
FCfor the Polish Brain Metastasis Consortium
for the Polish Brain Metastasis Consortium
RDRENATA DUCHNOWSKA
RENATA DUCHNOWSKA
RPRafał Pęksa
Rafał Pęksa
BRBarbara Radecka
Barbara Radecka
TMTomasz S. Mandat
Tomasz S. Mandat
JJJacek Jassem
Jacek Jassem
A better understanding of immune response in breast cancer brain metastases (BCBM) may prompt new preventive and therapeutic strategies. Immunohistochemical expression of stromal tumor-infiltrating lymphocytes (TILs: CD4, CD8, CTLA4), macrophage/microglial cells (CD68), programmed cell death protein 1 receptor (PD-1), programmed cell death protein 1 receptor ligand (PD-L)1, PD-L2 and glial fibrillary acid protein was assessed in 84 BCBM and their microenvironment. Median survival after BCBM excision was 18.3 months (range 0–99). Median number of CD4+, CD8+ TILs and CD68+ was 49, 69 and 76 per 1 mm2, respectively. PD-L1 and PD-L2 expression in BCBM was present in 53 % and 36 % of cases, and was not related to BCBM phenotype. PD-1 expression on TILs correlated positively with CD4+ and CD8+ TILs (r = 0.26 and 0.33), and so did CD68+ (r = 0.23 and 0.27, respectively). In the multivariate analysis, survival after BCBM excision positively correlated with PD-1 expression on TILs (hazard ratio (HR) = 0.3, P = 0.003), CD68+ infiltration (HR = 0.2, P < 0.001), brain radiotherapy (HR = 0.1, P < 0.001), endocrine therapy (HR = 0.1, P < 0.001), and negatively with hormone-receptor-negative/human epidermal growth factor receptor 2 (HER2)-positive phenotype of primary tumor (HR = 2.6, P = 0.01), HER2 expression in BCBM (HR = 4.9, P = 0.01). PD-L1 and PD-L2 expression is a common occurrence in BCBM, irrespective of primary tumor and BCBM phenotype. Favorable prognostic impact of PD-1 expression on TILs suggests a beneficial effect of preexisting immunity and implies a potential therapeutic role of immune checkpoint inhibitors in BCBM.

16 August 2012 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
RDRENATA DUCHNOWSKA
RENATA DUCHNOWSKA
RDRafal Dziadziuszko
Rafal Dziadziuszko
TTTomasz Trojanowski
Tomasz Trojanowski
TMTomasz S. Mandat
Tomasz S. Mandat
WOWaldemar Och
Waldemar Och
TCthe Polish Brain Metastasis Consortium
the Polish Brain Metastasis Consortium
Introduction: We investigated the status of estrogen receptor alpha (ERα), progesterone receptor (PR), and epidermal growth factor receptor 2 (HER2) in primary tumor and in the corresponding brain metastases in a consecutive series of breast cancer patients. Additionally, we studied factors potentially influencing conversion and evaluated its association with survival. Methods: The study group included 120 breast cancer patients. ERα, PR, and HER2 status in primary tumors and in matched brain metastases was determined centrally by immunohistochemistry and/or fluorescence in situ hybridization. Results: Using the Allred score of ≥ 3 as a threshold, conversion of ERα and PR in brain metastases occurred in 29% of cases for both receptors, mostly from positive to negative. Conversion of HER2 occurred in 14% of patients and was more balanced either way. Time to brain relapse and the use of chemotherapy or trastuzumab did not influence conversion, whereas endocrine therapy induced conversion of ERα (P = 0.021) and PR (P = 0.001), mainly towards their loss. Receptor conversion had no significant impact on survival. Conclusions: Receptor conversion, particularly loss of hormone receptors, is a common event in brain metastases from breast cancer, and endocrine therapy may increase its incidence. Receptor conversion does not significantly affect survival.

1 February 2018 in Cytokine & Growth Factor Reviews
Verified
Journal Article
Closed access
PWPiotr Wojdasiewicz
Piotr Wojdasiewicz
ŁPŁukasz A. Poniatowski
Łukasz A. Poniatowski
PNPaweł Nauman
Paweł Nauman
TMTomasz S. Mandat
Tomasz S. Mandat
Agnieszka Paradowska-GoryckaAgnieszka Paradowska-Gorycka
Agnieszka Paradowska-Gorycka
RGRobert Gasik
Robert Gasik

1 January 2012 in Frontiers in Integrative Neuroscience
Verified
Journal Article
Open access
GPGilberto Pizzolato
Gilberto Pizzolato
TMTomasz S. Mandat
Tomasz S. Mandat
Application of the stereotactic technique to neurosurgery and introduction of deep brain stimulation (DBS) were the milestones in surgical neuromodulation. Presently, the role of the DBS in the treatment of clinically and epidemiologically relevant movement disorders is widely accepted and DBS procedures are performed in many clinical centres worldwide. Here we review the current state of the art of DBS treatment for the most common movement disorders: Parkinson’s disease, essential tremor, and dystonia. In this review, we give a brief description of the candidate patient selection criteria, the different anatomical targets for each of these condition, and expected outcomes as well as possible side effects.

1 December 2009 in Journal of Neurosurgery
Verified
Journal Article
Closed access
TMTomasz S. Mandat
Tomasz S. Mandat
BBBoguslaw Brozyna
Boguslaw Brozyna
GKGrzegorz Krzymanski
Grzegorz Krzymanski
JPJan K. Podgorski
Jan K. Podgorski
The authors describe a simple and low-cost technique for image-guided cannulation of the foramen ovale during treatment of medically refractory trigeminal neuralgia using percutaneous radiofrequency rhizotomy. Computed tomography-guided neuronavigation and the noninvasive ear, nose, and throat Small Active Frame system were applied for visualization of cannulation of the foramen ovale in the awake patient. Use of invasive head-clamp fixation was unnecessary. Three patients were treated using this technique in which the foramen ovale was reached using a single tract. No adverse effects of this technique were reported. The potential benefits and disadvantages of this method are presented.

Verified
Journal Article
Open access
PDF file
WCWojciech Czyzewski
Wojciech Czyzewski
JLJakub Litak
Jakub Litak
JSJan Sobstyl
Jan Sobstyl
TMTomasz S. Mandat
Tomasz S. Mandat
KTKamil Torres
Kamil Torres
GSGrzegorz Staśkiewicz
Grzegorz Staśkiewicz
Aquaporins (AQPs), particularly AQP4, play a crucial role in regulating fluid dynamics in the brain, impacting the development and resolution of edema following traumatic brain injury (TBI). This review examines the alterations in AQP expression and localization post-injury, exploring their effects on brain edema and overall injury outcomes. We discuss the underlying molecular mechanisms regulating AQP expression, highlighting potential therapeutic strategies to modulate AQP function. These insights provide a comprehensive understanding of AQPs in TBI and suggest novel approaches for improving clinical outcomes through targeted interventions.